Collegium Pharmaceutical (NASDAQ:COLL) EVP Sells $626,223.69 in Stock

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Scott Dreyer sold 16,389 shares of Collegium Pharmaceutical stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $38.21, for a total value of $626,223.69. Following the completion of the transaction, the executive vice president owned 103,613 shares of the company’s stock, valued at $3,959,052.73. The trade was a 13.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Scott Dreyer also recently made the following trade(s):

• On Wednesday, August 13th, Scott Dreyer sold 4,861 shares of Collegium Pharmaceutical stock. The stock was sold at an average price of $38.03, for a total transaction of $184,863.83.

Collegium Pharmaceutical Stock Down 1.0%

Shares of NASDAQ:COLL opened at $39.11 on Friday. Collegium Pharmaceutical, Inc. has a fifty-two week low of $23.23 and a fifty-two week high of $42.29. The firm’s 50 day moving average price is $32.42 and its 200 day moving average price is $30.05. The company has a quick ratio of 1.10, a current ratio of 1.18 and a debt-to-equity ratio of 3.27. The stock has a market cap of $1.23 billion, a price-to-earnings ratio of 37.61 and a beta of 0.68.

Collegium Pharmaceutical announced that its Board of Directors has authorized a share buyback plan on Monday, July 7th that permits the company to repurchase $150.00 million in outstanding shares. This repurchase authorization permits the specialty pharmaceutical company to repurchase up to 15.4% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s management believes its shares are undervalued.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Piper Sandler reiterated a “neutral” rating and set a $37.00 target price (up previously from $36.00) on shares of Collegium Pharmaceutical in a research note on Friday, May 9th. HC Wainwright raised Collegium Pharmaceutical to a “strong-buy” rating and set a $44.00 price target for the company in a report on Monday, August 11th. Finally, Wall Street Zen raised Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 9th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, Collegium Pharmaceutical currently has a consensus rating of “Buy” and an average price target of $42.33.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several large investors have recently modified their holdings of COLL. State of Wyoming grew its position in shares of Collegium Pharmaceutical by 113.9% during the second quarter. State of Wyoming now owns 12,297 shares of the specialty pharmaceutical company’s stock worth $364,000 after acquiring an additional 6,547 shares during the last quarter. Public Sector Pension Investment Board boosted its stake in shares of Collegium Pharmaceutical by 7.4% during the second quarter. Public Sector Pension Investment Board now owns 109,795 shares of the specialty pharmaceutical company’s stock worth $3,247,000 after buying an additional 7,549 shares during the period. Tower Research Capital LLC TRC grew its holdings in shares of Collegium Pharmaceutical by 444.6% during the second quarter. Tower Research Capital LLC TRC now owns 3,551 shares of the specialty pharmaceutical company’s stock worth $105,000 after buying an additional 2,899 shares during the last quarter. Rubric Capital Management LP increased its position in Collegium Pharmaceutical by 5.3% in the 2nd quarter. Rubric Capital Management LP now owns 3,157,743 shares of the specialty pharmaceutical company’s stock valued at $93,374,000 after acquiring an additional 157,743 shares during the period. Finally, Engineers Gate Manager LP increased its position in Collegium Pharmaceutical by 165.7% in the 2nd quarter. Engineers Gate Manager LP now owns 70,077 shares of the specialty pharmaceutical company’s stock valued at $2,072,000 after acquiring an additional 43,705 shares during the period.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.